Preclinical studies have adduced a wealth of evidence to support the ability of specific SphK2 inhibitor ABC294640, which is currently being tested in cancer patients in phase I/II clinical trials, to increase cancer cell response to chemotherapy. The gene discussed is SPHK2; the disease is cancer.